萬隆控股集團(00030.HK)發CB籌7.3億元 換股價每股0.258元
萬隆控股集團(00030.HK)公布,與雲南白藥集團訂立認購協議,公司將向其發行本金總額7.3億元之可換股債券,認購價等於可換股債券之本金總額。初步換股價每股換股股份0.258元,較昨日(14日)收市價輕微折讓0.77%。即於可換股債券所隨附換股權獲全面行使時,將配發及發行合共28.29億股換股股份,佔公司經擴大後股本之30.5%。
公司料是次發行所得淨額7.28億元,將用於工業大麻及CBD相關的業務發展、研發、投資、收購或其他相關應用及機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.